HDTs are made from drug-dendrimer conjugates and in four health volunteer safety studies and 2 Phase 2 studies we find repeated safety in human subjects some of whom have been dosed chronically for forty weeks. This is exciting for us and patients who could benefit from our drug

"It’s easy to think that machine learning is a completely digital phenomenon, made possible by computers and algorithms that can mimic brain-like behaviors. But the first machines were analog and now, a small but growing body of research is showing that mechanical systems are

We are developing a radiopharmaceutical that targets TAM (tumor associate macrophage) without any targeting ligand. Thought that was impossible, think again. Because our radiopharmaceutical is an HDT (hydroxyl dendrimer therapeutic) it comes with minimum toxicity to patients.

Checkpoint inhibitors only work in 15-40% of patients who have cancers. They are miracle drugs but could use some help. Ashvattha Therapeutics has developed a radiopharmaceutical that can solve the problem.

Ashvattha is the first therapeutics platform to target and reprogram macrophage and microglia (two important immune cells) which are known to be responsible for neurological disorders to cancer, ophthalmic diseases to autoimmune disorders. We're excited to partner with

💪🙌

Time to Change the Treatment Paradigm - No More Needles in the Eye It's 2025, and we have an alternative to the pain faced by millions of wAMD and DME patients - an at-home subcutaneous administration once per month that treats both eyes, dramatically reducing the need for the

Feels like Saildrone has been waiting for this realization to dawn on the navy. They’ve already built what we can use to win the next conflict.

Some good news on our Phase 2 open label study for wet AMD and DME. 🔥 > Migaldendranib therapy obviates or reduces the need for more invasive in-the-eye injections > Multiple subcutaneous doses safe and well-tolerated > 69% reduction in anti-VEGF intravitreal (IVT) treatment

Congrats Will Bruey, delian and the Varda Space Industries team. Launching a capsule that can test new formulations / drugs, hypersonic capabilities, and heat shield materials is sick! A new level of abundance coming up!🙌🚀💊

Nylon 6 CF super material!💪

👀

We need data on new classes of protein binders beyond what exists in the literature!

The results only get better! Ashvattha is showing improved interim results for our drug Migaldendranib for DME (Diabetic Macular Edema) and Wet AMD (Age-related Macular Degeneration). If this continues, not only could we achieve our goal of one single intravitreal injection every

Today we’re announcing two pieces of news: 1) We raised $187 million Series C led by Natural Capital and Shrug Capital. 2) We’re expanding into a new lab space to begin work on biologics. Soon, space reentry will be ordinary and drugs made in orbit will be part of everyday care.

Excited to announce that we've raised a $187m Series C!! Plenty of fuel to continue accomplishing our mission To expand the economic bounds of humankind You'll know we've gotten there when you look up at the night sky & see Varda laboratories in orbit the size of cities

1/ Natural Capital Natural Capital is thrilled to co-lead Varda Space Industries $187 MM Series C with Shrug Capital , alongside Founders Fund , Peter Thiel, Lux Capital , Khosla Ventures , Raymond Tonsing & others. Also excited to announce that I have joined the board. Jay Z Moshe Lifschitz

Psyched to join delian, Will Bruey and Varda Space Industries on this quest! Thanks to Ravi Tanuku, Moshe Lifschitz for championing this. 💪

Some learnings from the last 12 months. At Aether our mission has always been to build a future of abundance for the human race. We plan on doing this by using our AI to design totally new classes of proteins that can assemble complex products in modular factories (more on this